Cancer Immunotherapy: Technologies and Global Markets

Report Highlights

The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.

Report Includes

• 75 data tables and 54 additional tables
• An analysis of the global cancer immunotherapy market
• Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
• Estimates of the market size and revenue prospects for the global market, along with a market share analysis by therapy type, cancer type, and region
• Coverage of treatments that are in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends
• Evaluation of recent patent activity and key granted and published patents in the industry
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Profiles of leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., and AstraZeneca

Report Scope

This report provides a detailed analysis of the cancer immunotherapy market. It highlights cancer immunotherapy’s current and future market potential and analyzes the competitive environment, covering regulatory scenarios, drivers, restraints and opportunities. The report provides market trends in cancer immunotherapy for the forecast period 2024–2029 using data from 2023 and estimates from 2024. It includes projections of compound annual growth rates (CAGRs) through 2029 and provides the market shares of key players in this market.

In this analysis, the cancer immunotherapy market is segmented by therapy types, cancer types and geographic regions. By therapy type, the market is segmented into the following: checkpoint inhibitors, monoclonal antibodies, adoptive cell therapies, cytokine therapy, cancer vaccines, oncolytic virus therapy and other immunotherapies. It is segmented by cancer type into melanoma, leukemia, lymphoma, myeloma, lung cancer, breast cancer, colorectal cancer and other cancers.

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The regional analysis includes details about major countries such as the U.S., Canada, Germany, the U.K., Italy, Spain, France, Japan, China, South Korea, Australia and India.

The report aims to:

• Analyze therapies and types of cancer.
• Analyze global market size and segmentation.
• Understand market constraints and drivers.
• Provide detailed market forecasts for 2029.
• Assess market shares, competitiveness and industry structure.
• Identify potential long-term impacts on the cancer immunotherapy market.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.